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ABSTRACT
The graft-versus-leukemia (GVL) effect is often coexpressed with graft-versus-host disease (GVHD), although
the temporal kinetics of these responses have not been critically examined. To evaluate this question in the
absence of the confounding effects of the conditioning regimen, 23 patients who received donor lymphocyte
infusions from HLA-identical siblings and subsequently developed GVHD and/or a GVL response were
studied to determine whether these were temporally synchronous events. The GVL effect occurred signifi-
cantly earlier than GVHD, being that 19 of 23 patients had a sustained GVL response that antedated the onset
of clinical GVHD. The median difference between time to GVL and graft-versus-host (GVH) reactivity in the
entire cohort was 14 days. There was no correlation between total T-cell dose and the relative onset of GVL
versus GVH reactivity, indicating that temporal dissociation of GVL and GVH responses was not a function of
the absolute number of infused donor T cells. These data support existing murine bone marrow transplanta-
tion studies indicating that GVL and GVH responses are not temporally synchronous events and raise the
possibility that targeted elimination of alloreactive donor T cells after bone marrow transplantation may be an
effective strategy for the separation of GVL/GVH reactivity.
© 2004 American Society for Blood and Marrow Transplantation
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hNTRODUCTION
Allogeneic bone marrow transplantation (BMT) is
urative in part because of a graft-versus-leukemia
GVL) effect mediated primarily by immunocompetent
onor T cells transferred in the marrow graft [1]. Un-
ortunately, in most instances, GVL reactivity is also
oexpressed with graft-versus-host disease (GVHD),
hich is the major complication of allogeneic marrow
ransplantation [2,3]. The precise relationship between
he T cells that mediate the GVL effect and those re-
ponsible for the initiation of GVHD has not been fully
esolved. The preponderance of experimental and clin-
cal data support the existence of GVL effector popula-
ions that have speciﬁcity either for antigens expressed r
B&MTxclusively on leukemia cells or antigens that are shared
n both leukemia cells and host tissues [3-7]. An under-
ying assumption is that GVL and graft-versus-host
GVH) responses are synchronous events, and attempts
o dissociate these 2 events have been predicated on the
election of donor T cells that have preferential speci-
city for leukemia as opposed to host cell antigens
8-12]. Studies in animal models, however, have indi-
ated that GVL and GVH reactivity are not necessarily
emporally concordant but can occur with differential
inetics after allogeneic BMT [13,14]. The relevance of
hese ﬁndings to clinical BMT, however, has not been
tudied. To examine whether this supposition is valid in
umans, we selected a population of patients who had
eceived donor lymphocyte infusions (DLI) for the treat-
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7ent of relapsed leukemia after allogeneic marrow trans-
lantation, in whom the temporal kinetics of GVL and
VH reactivity could be examined in the absence of the
onfounding effects of the conditioning regimen.
ATERIALS AND METHODS
atient Population
Between 1992 and 2002, 46 adult patients received
LI from HLA-identical sibling donors at the Med-
cal College of Wisconsin for treatment of relapsed
ematologic malignancies after allogeneic BMT. A
etrospective analysis of these patients and their clin-
cal course after DLI was approved by the Internal
eview Board of the Medical College of Wisconsin.
atients were excluded from this analysis if they re-
eived DLI for posttransplantation lymphoprolifera-
ive disorder (n  1) or received DLI with thymidine
inase–transduced activated T cells [15] (n  2). Pa-
ients were also not included who were treated with
hemotherapeutic agents immediately before or after
LI before a response could be evaluated (n  10);
ith rituxan (n  2); or with prolonged (2 weeks)
ost-DLI therapy with immunomodulating agents
uch as interferon-alfa that were capable of inducing a
irect antileukemic effect (n  4). Patients with
hronic myelogenous leukemia (CML) who were
reated with hydroxyurea to control increased white
lood cell counts immediately after DLI were in-
luded because hydroxyurea has not been shown to
nduce cytogenetic responses in CML. Three patients
ho underwent a second transplantation immediately
fter DLI, were infused with granulocyte colony-stim-
lating factor–mobilized DLI, or had an unassessable
VL response were excluded.
efinitions of GVHD and GVL Reactivity
The onset of GVHD was deﬁned as the ﬁrst day
n which there was clinical or histologic evidence of
VHD. The onset of an antileukemic response was
eﬁned as the ﬁrst day on which there was evidence
f a cytogenetic response for patients with CML,
hereas a bone marrow examination demonstrating
orphologic remission was required for patients with
yelodysplastic syndrome. Evidence of a sustained
ecrease in serum paraprotein levels or computed to-
ographic scan evidence of nodal regression was re-
uired for response in multiple myeloma or non-
odgkin’s lymphoma, respectively. One patient with
ML who was treated in molecular relapse was
eemed to have responded after having a molecular
esponse as determined with a nested polymerase
hain reaction assay [16]. For a patient to be classiﬁed
s having had a GVL response, the morphologic,
erologic, cytogenetic, or molecular response had to
e sustained on at least 2 consecutive determinations. l
44ESULTS
Of the 24 patients who were evaluable for GVH
nd GVL reactivity on the basis of the criteria noted
reviously, 1 patient had no evidence of a GVH or
VL response and was excluded from the analysis.
hree patients had only GVHD, 2 had a GVL re-
ponse only, and 18 patients had evidence of both
VL and GVH reactivity. The demographics and the
emporal kinetics of the GVL and GVH responses in
hese 23 patients are presented in Table 1. In 13
atients the GVL response occurred before GVHD,
n 6 patients GVL and GVH responses were docu-
ented concurrently, and in 4 patients GVHD oc-
urred before or in the absence of a GVL response
Figure 1A). Statistical analysis with the sign test dem-
nstrated that the GVL response occurred signiﬁ-
antly earlier than the clinical expression of GVHD in
hese 23 patients (P  .049). The temporal kinetics of
VL and GVH responses in the patients who devel-
ped 1 or both are shown in Figure 1B. The difference
etween time to GVL and GVH reactivity was com-
uted for each patient, and the median difference was
etermined to be 14 days. The magnitude of the GVL
esponse at the time GVHD was documented was
hen evaluated in 18 patients who had evidence of
oth GVL and GVH reactivity. Ten patients had a
omplete cytogenetic or hematologic response that
ccurred either before or concurrently with the onset
f GVHD, whereas 7 patients had a partial cytoge-
etic/molecular response (for CML patients) or a he-
atologic response before GVHD became clinically
vident (Table 1). In only 1 patient did GVHD
resent before any antileukemic response was ob-
erved.
ISCUSSION
These data indicate that GVL and GVH reactivity
re not temporally synchronous events but can occur
ith differential kinetics after infusion of alloreactive
onor T cells. In the vast majority of patients, the
VL response antedated clinical GVHD. Moreover,
he magnitude of the GVL response in many of these
atients was such that they were in remission before or
t the time GVHD was documented, demonstrating
hat a quantitatively robust GVL response can occur
efore GVHD initiation. There was no correlation
etween the total T-cell dose and the relative onset of
VL versus GVH reactivity (Figure 1C; P  .67, r 
0.01 by Pearson correlation coefﬁcient), indicating
hat temporal dissociation of GVL and GVH re-
ponses was not a function of the absolute number of
nfused donor T cells. Although most patients in this
tudy had CML, there is evidence from animal models
hat this observation may be valid in other hemato-
ogic diseases as well. Boranic and Tonkovic [13] ex-
Table 1. Characteristics of Patients with GVL and/or GVH Responses
Patient
No.
Age
(y) Sex
Disease
Status at DLI
DLI T-Cell
Dose
( 108)
Onset of GVL
after DLI
(days)
Onset of GVHD
after DLI (days)
Disease Response
to DLI at GVHD
Onset
Magnitude of GVL
Response at GVHD
Onset*
Current Clinical
Status†
225 35 F CML, AP 4.0 67 89 Cy Rem 90%30% Ph Dead, GVHD, day 2120
306 43 M CML, AP 2.3 75 37 None NA CCR, day 4080
335 36 M CML, Cy Rel 3.4 27 34 Cy Resp 100%390% Ph CCR, day 3163
350 24 F CML, CP 2.6 20 63 Cy Rem 80%30% Ph CCR, day 3550
352 40 F CML, CP 1.0 NA 36 None NA Dead, relapse, day 697
357 48 F CML, CP 2.7 49 49 Cy Resp 95%380% Ph Dead, sepsis, day 1477
386 52 M MDS 3.0 NA 50 None NA Dead, sepsis, day 57
487 56 M CML, CP 0.1 32 32 Cy Rem 100%30% Ph Dead, GVHD, day 71
506 25 M CML, AP 2.8 82 124 Cy Resp 100%390% Ph CCR, day 3226
563 42 M CML, CP 2.6 27 94 Cy Resp 95%33% Ph CCR, day 3228
593 30 M CML, BC 3.0 NA 31 None NA Dead, GVHD, day 56
602 35 M CML, CP 2.9 59 157 Cy Rem 100%30% Ph Dead, relapse, day 375
732 50 F CML, CP 0.1 27 148 Cy Rem 5%30% Ph CCR, day 2562
755 45 F CML, Cy Rel 0.1 53 67 Cy Resp 70%340% Ph Dead, sepsis, day 1024
801 48 M MM 1.0 36 36 Hem Resp 2IgG paraprotein CR, day 2480
881 34 M CML, CP 2.6 97 97 Cy Rem 80%30% Ph Dead, relapse, day 456
882 35 M CML, CP 2.5 26 48 Cy Rem 90%30% Ph CCR, day 1182
884 28 M CML, Cy Rel 3.0 50 50 Cy Rem 30%30% Ph CCR, day 3030
927 42 M CML, CP 0.9 82 96 Cy Rem 100%30% Ph CCR, day 1629
1047 42 F NHL, Rel 0.6 146 NA CR Nodal regression by CT CR, day 825
1148 44 M CML, Mol Rel 1.1 55 55 Mol Resp 1%32% round PCR MR, day 676
1267 52 M MDS 0.1 85 133 CR 27%30% blasts Dead, relapse, day 679
1321 28 F CML, Cy Rel 0.5 81 NA Cy Rem 30%30% Ph CCR, day 571
Cy Rel indicates cytogenetic relapse; Mol Rel, molecular relapse; NHL, non-Hodgkin lymphoma; AP, accelerated phase; CP, chronic phase; Cy Resp, cytogenetic response; Cy Rem, cytogenetic
remission; Mol Resp, molecular response; CCR, complete cytogenetic response; MR, molecular remission; NA, not applicable; MDS, myelodysplastic syndrome; MM, multiple myeloma; Ig,
immunoglobulin; CT, computed tomography; PCR, polymerase chain reaction; BC, blast crisis; Rel, relapsed; Hem Resp, hematological response.
Response criteria were deﬁned as follows: cytogenetic response, a decrease in the percentage of Philadelphia chromosome–positive (Ph) metaphases on marrow examination; cytogenetic remission, the
absence of Ph metaphases; molecular response, a decrease in the bcr/abl signal with a semiquantitative nested PCR approach [16]; complete remission (CR), normal blood counts and 5% marrow
blasts (for MDS) or complete regression of adenopathy (for NHL).
*The magnitude of the GVL response was assessed by determining the extent of antileukemic response at the time GVHD was ﬁrst documented. This was assessed by analysis of the most recent marrow
examination that antedated GVHD. This was done to avoid biasing the results in favor of a more complete GVL response at the time of GVHD. In patient 884, a marrow examination was performed
5 days after the onset of GVHD and showed cytogenetic remission. Because of the proximity of this examination to the onset of GVHD and the extent of the response, this patient was deemed to
have had concurrent onset of GVL and GVH reactivity.
†Patients 357 and 755, who died from sepsis, were in cytogenetic remission at the time of their demise.
T
em
poralD
iscordance
betw
een
G
V
L
and
G
V
H
R
esponses
745
B
B
&
M
T
a
e
w
r
e
w
m
a
k
a
w
e
d
u
o
g
l
a
e
t
t
c
p
m
d
c
c
p
e
t
b
g
w
p
c
s
b
r
t
e
n
a
i
c
c
e
h
r
s
a
t
d
n
u
n
b
t
R
F
(
b
S
a
P. Hari et al.
7mined the tempo of myeloid and lymphoid leukemia
radication in mice that underwent transplantation
ith allogeneic marrow grafts by adoptively transfer-
ing cells from various organs into secondary recipi-
nts. They demonstrated that by 7 days after BMT,
hen mice had yet to develop clinical GVHD, leuke-
ia could no longer be transferred into secondary
nimals. In more recent studies, we examined the
inetics of leukemia eradication by using a murine
cute lymphoblastic leukemia transplant model in
hich donor T cells were genetically engineered to
xpress a thymidine kinase suicide gene [14]. These
ata demonstrated that, under conditions in which
ntreated mice could not be cured of leukemia with-
ut dying from GVHD, the timely administration of
anciclovir was able to result in the elimination of
eukemia without lethal GVHD, indicating that GVL
nd GVH reactivity were temporally discordant
vents. In both studies, mice were administered pre-
ransplantation total body irradiation; this indicates
hat this observation is also valid in conditioned re-
ipients. Findings by Michalek et al. [11] further sup-
ort this premise in human acute myelogenous leuke-
ia. Using T-cell receptor- CDR3 sequences to
eﬁne putative GVH- and GVL-reactive T-cell
lones, they were able to track the appearance of these
lones in the peripheral blood of a patient after trans-
lantation. These studies showed that there was an
arlier and quantitatively greater increase in the puta-
ive GVL-reactive T-cell clone in the peripheral
lood in comparison to the GVH-reactive clone, sug-
esting that the temporal kinetics of these 2 responses
ere discordant. Collectively, these data provide sup-
ort for the premise that GVL and GVH responses
igure 1. Temporal kinetics of GVL and GVH responses. A, Num
white bar), in whom a GVL response antedated GVHD (black bar),
ar). B, Percentage of patients who had either a GVL (closed squar
catterplot of total T-cell dose versus the interval between the rela
nd GVH responses. Data points represent individual patients.an occur with differential kinetics after allogeneic
46tem cell transplantation. Why leukemia cells would
e preferentially targeted by donor T cells is an un-
esolved but interesting question. Possible explana-
ions include, but are not limited to, a more restricted
xpression of antigens on the leukemia for which do-
or T cells have a greater precursor frequency or
fﬁnity, and the relative accessibility of leukemia cells
n marrow and nodal sites that confer enhanced sus-
eptibility to immune-mediated attack.
The ﬁndings of this study may have important
linical implications given the technology that now
xists to regulate donor T-cell survival in vivo in
umans. The incorporation of a suicide gene through
etroviral transduction [17,18] or the triggering of
uicide genes via chemical dimerizing agents [19,20]
re examples of existing and emerging technologies
hat allow for the selective elimination of alloreactive
onor T cells. When coupled with sensitive cytoge-
etic and molecular tools for the monitoring of resid-
al disease, the timed elimination of alloreactive do-
or T cells in patients deemed to be in remission may
e an effective way to separate GVL and GVH reac-
ivity after BMT.
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